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Abstract
Background: There are few studies comparing pharmaceutical costs and the use of medications
between immigrants and the autochthonous population in Spain. The objective of this study is to
evaluate whether there are differences in pharmaceutical consumption and expenses between
immigrant and Spanish-born populations.
Methods: Prospective observational study in 1,630 immigrants and 4,154 Spanish-born individuals
visited by fifteen primary care physicians at five public Primary Care Clinics (PCC) during 2005 in
the city of Lleida, Catalonia (Spain). Data on pharmaceutical consumption and expenses was
obtained from a comprehensive computerized data-collection system. Multinomial regression
models were used to estimate relative risks and confidence intervals of pharmaceutical
expenditure, adjusting for age and sex.
Results: The percentage of individuals that purchased medications during a six-month period was
53.7% in the immigrant group and 79.2% in the autochthonous group. Pharmaceutical expenses and
consumption were lower in immigrants than in autochthonous patients in all age groups and both
genders. The relative risks of being in the highest quartile of expenditure, for Spanish-born versus
immigrants, were 6.9, 95% CI = (4.2, 11.5) in men and 5.3, 95% CI = (3.5, 8.0) in women, with the
reference category being not having any pharmaceutical expenditure.
Conclusion:  Pharmaceutical expenses are much lower for immigrants with respect to
autochthonous patients, both in the percentage of prescriptions filled at pharmacies and the
number of containers of medication obtained, as well as the prices of the medications used. Future
studies should explore which factors explain the observed differences in pharmaceutical expenses
and if these disparities produce health inequalities.
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Background
Immigration in Spain has increased dramatically in the
last decade. In 1996, immigrants represented 1.4% of the
total Spanish population, and by 2006 had reached
10.8% [1].
In Spain, there is a National Health System (NHS),
financed mainly by taxes, which provides universal and
free health coverage including primary, specialized and
hospital health care [2]. Primary care physicians represent
the entry point to the health system. In Spain, immigrants
may register in their municipality of residence to have
access to health care, regardless of their legal status. How-
ever, a number of immigrants are not registered because
they are unaware of the process, fear legal authorities'
access to the database, or their municipal government
rejects their registration [3]. Some immigrants, primarily
of sub-Saharan origin, wait for weeks to register with the
municipal authorities because they do not have a passport
or other documentation to validate their identity. Other
immigrants register very rapidly.
Pharmaceutical consumption may be related to the health
care system of the country and the type of insurance of the
user. Lundberg et al studied the effect of user charges on
the use of prescription medicines [4]. They concluded that
the young, those with poor health status, low education
and low income are most likely to decrease consumption
of prescription drugs when user charges increase. In Spain,
user co-payments are restricted to pharmaceutics. The user
pays 40% of the price of medication prescribed by NHS
doctors (100% of private prescription drugs), with the
exception of inpatients and 'exempt' groups (retired,
handicapped, and people who have suffered occupational
accidents) and drugs administered in hospitals, which are
provided without cost to the patient. Drugs for chronic
diseases are subject to 10% cost sharing when explicitly
prescribed by NHS doctors to patients identified as chron-
ically ill [5].
Due to the recent nature of the migratory phenomenon in
our country, there are few studies of pharmaceutical costs
and the use of medications in immigrant populations,
and even fewer that compare their usage rates with those
of the autochthonous population. A report by the BBVA-
IEA foundation, directed by professor Guillem López-
Casasnovas analyzed the impact of immigration and
observed that, in Spain, immigrants consume less medica-
tion than expected [6]. Another study done in Almería
examined prescriptions written at an emergency room to
Muslims during Ramadan and observed that physicians
adapted their prescribing practices to prevent non-compli-
ance with treatment [7].
Gaskin et al, found that age and health status do not fully
explain observed disparities in prescription drug use [8].
According to the authors, racial and ethnic inequalities
may reflect the skepticism of patients with respect to med-
icine and health care in general, lower compliance with
medical advice, communication problems between doc-
tors and patients, and possibly differences in the prescrib-
ing habits of care-givers.
Nevertheless, according to community pharmacists, the
pharmaceutical attention that immigrants receive does
not differ from that provided to the autochthonous com-
munity, although they recognize that there are barriers
that impede adequate intervention in these patients [9].
In Lleida (Catalonia, Spain), the urban immigrant popu-
lation has grown from insignificant percentages some
years ago to 17% of the resident population in December
2006 [10]. This increase in the immigrant population
motivated us to evaluate whether there are differences in
health care services provided to immigrants, with regard
to pharmaceutical consumption and expenses, when
compared to the autochthonous population.
Methods
Setting
Lleida is a city located in northeast Spain, in the auto-
nomic region of Catalonia, with approximately 130,000
inhabitants, of which roughly 22,000 are immigrants. Its
economy is based on agriculture and commerce. Immi-
grants living in the area are primarily economic immi-
grants, whose countries of origin have much lower
incomes per capita than Spain. They are primarily men
(approximately 60%) and younger, on average, than the
Spanish-born population. Immigrants come mostly from
Latin America, the Maghreb, sub-Saharan Africa and East-
ern Europe.
Study design
Prospective observational study in immigrant and Span-
ish-born populations.
Study population
Patients visited by fifteen primary care physicians at five
Primary Care Clinics (PCC), located in neighborhoods
with the largest immigrant populations. These PCC
belong to the Catalan Health Institute (ICS), the main
public provider of health services in Catalonia.
The study was approved by the ethics committee of the
Hospital Universitari Arnau de Vilanova (Lleida, Spain).
Study period
From March 2005 to August 2005.BMC Health Services Research 2008, 8:35 http://www.biomedcentral.com/1472-6963/8/35
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Study sample and sample size considerations
Our sample size objective was to include approximately
385 individuals from each of the 4 largest groups of immi-
grants in the city (Latin America, Maghreb, sub-Saharan
Africa and Eastern Europe), in order to estimate propor-
tions by zone of origin with a sampling error of 0.05 or
lower. Therefore, we planned to include approximately
1,600 immigrants. Since the age distributions of immi-
grants and Spanish-born individuals are different, we
decided to select a random sample of 300 Spanish-born
individuals from each of the 15 participating physicians.
A sample of this size would allow us to assess associations
between origin group and pharmaceutical consumption,
adjusting by age and sex with multivariable models.
All immigrant patients visited by participating physicians
during the study period were included in the study, a total
of 1,630 immigrants. A sample of 4,500 Spanish-born
patients was selected from patients that were not coded as
immigrants. Of these individuals initially identified as
Spanish-born, 346 were excluded after review by partici-
pating physicians because their country of origin was not
coded or had errors, with the final number of autoch-
thonous patients being 4,154. Thus, the total number of
participants in the study was 5,784.
The study population was divided into groups by birth
region: Spain, Maghreb, Eastern Europe, Latin America,
Sub-Saharan Africa, other low-income countries (includ-
ing Asian countries) and high-income countries [11,12].
High-income countries were excluded from the study
because the sample was too small.
Native-born individuals were defined as individuals born
in Spain and immigrants as individuals from low- and
middle-income countries outside Spain.
Variables and data collection system
In Catalonia, since October 2001, it has been obligatory
for patients to use their health card to obtain medications
in pharmacies. Pharmacies provide the Catalan Health
Service with monthly computerized reports on each med-
ication dispensed, a Personal Identification Code (PIC),
and the prescription code, which are then linked with
other information sources providing information on the
doctor and health center that produced the prescription.
In Lleida, since 2001, there have been computerized
applications to take advantage of this information, always
ensuring the confidentiality of these data. Therefore, the
source of information in our study comes from the pre-
scription bills of pharmacies in Lleida, using a purpose
built computerized data-collection system.
The variables used in our study are: date of birth, gender,
number of containers of medication, and the price of the
medication dispensed. In the analysis of medication dis-
pensed, the ATC international classification (Anatomical
Therapeutic Chemical Classification System), which was
adopted by the WHO in 1996 and is official in Spain since
2003, was used. Taking the ATC classification as a base-
line, eight large prescription groups were studied:
- Medications for pathological hypertension or cardiac
insufficiency (therapeutic subgroups C02, C03, C07, C08,
C09).
- Medications for diabetic conditions treated with insulin
(subgroup A10A).
- Medication for diabetic conditions treated with oral anti-
diabetics (subgroup A10B).
- Medications for hyperlipemia (therapeutic subgroup
C10).
- Medications for asthma or COPD (therapeutic subgroup
R03).
- Medication for mental illness (subgroups N05A, N05B,
N05C y N06A).
- Medication for osteoarticular illness (subgroups M01,
M02, M05, H05BA, G03XC).
- Medications for ulcerative conditions (subgroups A02A,
A02B).
- Medications for infectious diseases (subgroup J01).
Each prescription group was analyzed during the study
period to determine the number of patients treated, the
amount of medication purchased, total expenditures for
the group, and expenditure per patient, both for the immi-
grant population and the autochthonous population.
Statistical Analysis
A descriptive analysis of pharmaceutical expenditures by
age group, gender, immigrant/autochthonous group and
region of origin was performed. A box-and-whisker plot,
which summarizes continuous data using five  summary
numbers (the lower quartile (Q1) minus 1.5 times the
inter-quartile range (Q3-Q1) or the smallest observation,
the lower  quartile (Q1), the median, upper quartile (Q3),
and Q3 plus 1.5 times the  inter-quartile range (Q3-Q1)
or the largest observation), was used to  obtain a graphical
comparison of pharmaceutical expenses.BMC Health Services Research 2008, 8:35 http://www.biomedcentral.com/1472-6963/8/35
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Multinomial regression models were estimated using
pharmaceutical expenditure as the dependent variable,
which was classified into four categories based on expend-
iture quartiles: no expense, low expense (0.1€–20€),
moderate expense (20€–150€) and elevated expense
(150€ – maximum). The multinomial regression models
make it possible to estimate the relative risks and their
confidence intervals by adjusting for the age and sex of the
participants.
Multiple linear regression was used to compare pharma-
ceutical expenditures between immigrants and autoch-
thonous populations, adjusted for the age and gender of
the individuals studied. The dependent variable was the
natural logarithm of pharmaceutical expenditures during
the study period. The logarithm of expense was used
because it had a more symmetric distribution than the
expense itself. Linear multiple regression models were
also obtained to evaluate the differences in the number of
containers of medications consumed during the study
period.
For the pharmacological study and analysis, medications
prescribed to the immigrant population were studied by
therapeutic groups. Due to the elevated prescription vol-
ume and/or general expense, the nine therapeutic groups
selected were the following: hypertension and cardiac fail-
ure, diabetes related: insulin and oral antidiabetics, hyperli-
pemia,  asthma and COPD,  mental health,  osteoarticular
diseases,  ulcerative diseases (prophylaxis and treatment),
and infectious diseases.
Because the immigrant sample included only 24 patients
over 64 years of age, all regression models were estimated
for patients under 65.
Results
Table 1 shows the demographic characteristics of the
study participants. Women were predominant in the auto-
chthonous group and mean age was greater (48.3 years)
with respect to the immigrants (30.7 years). Individuals of
Latin American (30%) origin predominated in the immi-
grant group, followed by individuals from the Maghreb
(27%). The percentage of individuals that purchased med-
ications in a six-month period was 53.7% in the immi-
grant group and 79.2% in the autochthonous group.
There were differences in pharmaceutical expenses
between immigrant and autochthonous patients in all age
groups and both genders. Table 2 shows the medians for
pharmaceutical expenditures, both for the overall sample
and for the group of patients that purchased medication
in the studied period. Data for immigrants over 64 years
of age is not reliable because of the small sample size.
When analyzing pharmaceutical expenses by region
within the overall immigrant sample, median expendi-
tures were 4.0€ for patients from the Maghreb, about 3.0€
for patients from Latin America and sub-Saharan Africa,
and 0€ for patients from Eastern Europe. When the anal-
ysis was restricted to patients that purchased medication,
median expenditures were greater among patients from
the Maghreb (18.3€), followed closely by Latin Americans
(17.3€), Eastern Europeans (13.1€), with the lowest
expenditures being in the sub-Saharan group (11.0€).
Figure 1 shows a box-and-whisker plot of the distribution
of pharmaceutical expenses, by immigrant and autoch-
thonous patients, over a six-month period. The middle
fifty percent of the immigrant group spent between 0€
and 17€, while the middle fifty percent of autochthonous
patients spent between 4.1€ and 219.7€. In immigrants,
the median expense (3.1€) was less than that of the auto-
chthonous patients (39.6€).
Table 1: Demographic characteristics of the study populations. Individuals visited at public Primary Care Centers in Lleida, Catalonia 
(Spain) during 2005.
Variables Immigrant (n = 1,630) Spanish-born (n = 4,154) Total (n = 5,784)
n (%) n (%) n (%)
Sex:
- Men 795 (48.8) 1,812 (43.6) 2,607 (45.1)
- Women 835 (51.2) 2,342 (56.4) 3,177 (54.9)
Age:
- Mean (SD) 30.7 (13.9) 48.3 (21.8) 43.4 (21.4)
Country of origin: 4,154 (100%) 4,154 (71.8)
- Latin America 487 (29.9) 487 (8.4)
- Eastern Europe 374 (22.9) 374 (6.5)
- Maghreb 443 (27.1) 443 (7.7)
- Sub-Saharan 298 (18.3) 298 (5.2)
- Other 28 (1.7) 28 (0.5)BMC Health Services Research 2008, 8:35 http://www.biomedcentral.com/1472-6963/8/35
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Table 2: Total pharmaceutical expenditures (in euros) in the 6 months after a visit to the Primary Care Center.
Overall sample Patients that purchased medication
Immigrants Spanish-born Immigrants Spanish-born
Median (N) Median (N) Median (N) Median (N)
Men
<= 24 0.0 (206) 5.3 (308) 12.8 (87) 20.2 (183)
25–44 2.3 (492) 6.8 (593) 11.1 (256) 23.0 (379)
45–64 8.9 (93) 49.0 (449) 25.4 (59) 85.9 (363)
>= 65 174.1 (4) 257.7 (462) 174.1 (4) 282.4 (430)
Women
<= 24 13.0 (264) 21.6 (339) 13.3 (126) 16.6 (212)
25–44 4.6 (448) 14.1 (710) 17.1 (264) 29.1 (531)
45–64 15.5 (103) 98.9 (584) 49.9 (73) 122.9 (523)
>= 65 0.0 (20) 286.3 (709) 247.2 (9) 310.5 (670)
Box-and-whisker plot of pharmaceutical expenditures in 6 months after a primary care visit, by immigrant status Figure 1
Box-and-whisker plot of pharmaceutical expenditures in 6 months after a primary care visit, by immigrant status.
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When evaluating the different categories of pharmaceuti-
cal expenses (Table 3), it was observed that Spanish-born
patients have a greater relative risk of elevated pharmaceu-
tical expenses than immigrants. In men, the relative risk of
Spanish-born versus immigrants increases from 1.2 for
the low expenditure category to 6.9 for the high expendi-
ture category, with the reference category being not having
any pharmaceutical expenditures. In women, the relative
risk of Spanish-born versus immigrants increases from 1.6
for the low expenditure category to 5.3 for the high
expenditure category.
We estimated the relative risks of elevated expenses by ori-
gin group for both genders together because the sample
sizes for each gender were too small. Relative risks of
being in the high expenditure category for Spanish-born
individuals versus immigrants were 4.6, 95% CI = (2.9,
7.2) for Latin American patients, 19.2, 95% CI = (7.0,
52.6) for Eastern European patients, 4.1, 95% CI = (2.4,
7.0) for patients from the Maghreb, 7.9, 95% CI = (3.2,
19.6) for Sub-Saharan patients and 6.5, 95% CI = (0.8,
52.6) patients from other countries.
Table 4 shows estimates obtained from the linear regres-
sion model of the logarithm of medical expenses, by ther-
apeutic group and for both genders. The exponential
function of the coefficients corresponds to the ratio
between expenses in the Spanish-born group and
expenses in the immigrant group. As the table shows,
coefficients obtained were positive for almost all thera-
peutic groups, which indicates greater spending among
autochthonous patients, adjusted for sex and age. For
Table 3: Relative risks (RR) of pharmaceutical expenses, by 
immigrant status, adjusted for age (Multinomial regression). 
Patients under 65 years old.
Grup of expenditure RR * p-value 95% CI
Men
Low expenditure
Spanish-born versus immigrants 1.2 0.12 (0.9, 1.5)
Moderate expenditure
Spanish-born versus immigrants 2.4 <0.001 (1.9, 3.2)
High expenditure
Spanish-born versus immigrants 6.9 <0.001 (4.2, 11.5)
Women
Low expenditure
Spanish-born versus immigrants 1.6 <0.001 (1.3, 1.9)
Moderate expenditure
Spanish-born versus immigrants 2.3 <0.001 (1.8, 2.9)
High expenditure
Spanish-born versus immigrants 5.3 <0.001 (3.5, 8.0)
(*) Relative Risk (RR) refers to the comparison of the categories 
mentioned with respect to not having any pharmaceutical 
expenditure. CI: confidence interval.
Note: The category of low expenditure corresponds to the quantity 
of 0.1€–20€, moderate expenditure is 20€–150€ and high 
expenditure is 150€ and higher.
Table 4: Linear regression estimates of the logarithm of the pharmaceutical expenses by immigrant status, adjusted for age. Patients 
under 65 years old.
Medication group Coefficient Ratio of expenses between Spanish-born and immigrant 
individuals * exp(coefficient)
p-value CI (95%)
Men
Hypertension or cardiac insufficiency 0.17 1.19 0.60 (-0.45, 0.79)
Insulin -0.11 0.90 0.84 (-1.15, 0.94)
Oral anti-diabetics 0.41 1.51 0.40 (-0.56, 1.38)
Hyperlipemia 0.58 1.79 0.05 (0.01, 1.14)
Asthma or COPD 0.26 1.30 0.43 (-0.39, 0.91)
Mental health 1.29 3.63 <0.001 (0.63, 1.94)
Osteoarticular 0.20 1.22 0.02 (0.03, 0.37)
Ulcerative pathology 0.54 1.72 0.003 (0.19, 0.89)
Infectious pathology 0.33 1.39 0.001 (0.14, 0.52)
Women
Hypertension or cardiac insufficiency 0.52 1.68 0.02 (0.08, 0.95)
Insulin 0.72 2.05 0.20 (-0.40, 1.84)
Oral anti-diabetics 0.88 2.41 0.07 (-0.07, 1.83)
Hyperlipemia 0.20 1.22 0.69 (-0.78, 1.18)
Asthma or COPD 0.34 1.40 0.35 (-0.37, 1.04)
Mental health 0.72 2.05 0.001 (0.28, 1.16)
Osteoarticular 0.19 1.21 0.08 (-0.02, 0.39)
Ulcerative pathology 0.36 1.43 0.01 (0.08, 0.65)
Infectious pathology 0.06 1.06 0.47 (-0.10, 0.22)
* The values in this column indicate the number of times that a Spanish-born individual spends in medication in relation to an immigrant of the same 
age, sex and medical condition.BMC Health Services Research 2008, 8:35 http://www.biomedcentral.com/1472-6963/8/35
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both genders, the mental health category had the highest
ratio of expenses between Spanish-born and immigrant
patients. Other therapeutic groups that showed statisti-
cally significantly higher expenses in the native-born were
ulcerative diseases, infectious diseases and osteoarticular dis-
eases  in men and hypertension  and  ulcerative diseases in
women. A trend towards a higher expenditure for the
Spanish-born was seen in the hyperlipemia category in men
and the oral anti-diabetics and osteoarticular diseases catego-
ries in women.
We analyzed whether there were differences between the
amount of containers of medication purchased at the
pharmacy, and we observed that Spanish-born patients
purchased more containers than immigrants during the
study period. For both genders, the greatest differences
were seen in the mental health category, where the Span-
ish-born purchased, on average, more containers than the
immigrants in the studied period (4 containers more in
men and 3 more in women). Spanish-born individuals
also purchased more containers of insulin and anti-dia-
betic medications, although the differences did not reach
statistical significance.
Discussion
This work reflects a large difference in pharmaceutical
expenses between Spanish-born and immigrant patients.
The mean expenditure per immigrant was six times less
than that of the Spanish-born group and a larger propor-
tion of the Spanish-born individuals purchased medica-
tion (four out of five) with respect to the immigrant group
(one out of two). The medication group where the differ-
ences were highest was mental health. Relative risks of
Spanish-born versus immigrants for being in the highest
quartile of pharmaceutical expenditure were 6.9 for men
and 5.3 for women. The origin groups that had the lowest
risk of being in the high expenditure group were Eastern
European and Sub-Saharan patients.
These differences may be influenced by several factors.
The first factor is age, since the immigrants treated in pri-
mary care centers were younger than their autochthonous
counterparts. When the analysis is adjusted for age or the
analysis is restricted to individuals under 65 years old, the
differences in pharmaceutical expenditures persist, and
are statistically significant.
The second factor which may influence pharmaceutical
consumption is compliance. In Spain, medications are
sold in pre-packaged quantities (e.g. 24 doses), and
patients often have to "over-purchase" needed medica-
tions to comply with the physicians prescribed treatment,
e.g. purchase two packages of 10 daily doses of medica-
tion for two weeks treatment, leaving 6 doses unused. The
results of the present study show that immigrants pur-
chase less containers of medication than autochthonous
patients for pharmaceutical treatment within the same
medication group. Immigrants are systematically purchas-
ing less medication for treatment of the same types of dis-
eases. This possible lack of adherence to a therapeutic
regimen may be based in alternative medical treatments
followed by immigrants, communication problems
between patients and caregivers, lack of understanding of
the Spanish medical system, financial disincentives to
"over-purchase" instead of "under medicate", or other fac-
tors [13].
The third possible differential factor is a relationship with
the price of the medication prescribed. In fact, we have
observed that medications prescribed to immigrants are
statistically significantly less expensive within the mental
health category in both genders, as well as the ulcerative dis-
eases, infectious diseases and osteoarticular diseases categories
in men and anti-hypertension and ulcerative diseases catego-
ries in women. Given that most patients must pay a part
of the cost of pharmaceutical treatment, it is possible that
physicians prescribe less expensive medications to immi-
grants in order to facilitate compliance.
Inequalities in pharmaceutical prescribing by race have
been studied intensely in the United States. A study
released in the United States in 2005 reports that black
patients spend an average of $723.5 less on mental health
medications than white patients [14]. Another study,
from Briesacher et al, found differences in prescribing pat-
terns in patients with diabetes, hypertension and ischemic
heart disease [15]. Patients were classified into three
groups: non-Hispanic Whites, non-Hispanic Blacks, and
Hispanics. In all pathology groups, white patients spent
between 20% and 40% more than the rest. Black and His-
panic patients were prescribed less medication and
cheaper drugs when treating chronic conditions. These
differences remained after adjusting for age, diagnostic
pathology, and type of insurance. Gaskin, in a 2006 study
in which total pharmaceutical expense was analyzed, esti-
mated that if Black and White individuals had the same
demographic characteristics, White individuals would pay
8.9% more in prescription medications than Black indi-
viduals [8]. Furthermore, in 2002 Chen analyzed pediatric
prescriptions and found that Black children were pre-
scribed less medication than White children, with an odds
ratio of 0.67 [16]. As could be expected, children without
medical insurance received less medication than those
that had insurance. Nevertheless, according to Chen,
White children were prescribed more expensive medica-
tions than Black, Asian, Hispanic and Native American
children, and children from wealthy families spent nearly
double the amount on prescription medication as chil-
dren from families in the lower socioeconomic levels. Sur-
prisingly, the differences between racial and ethnic groupsBMC Health Services Research 2008, 8:35 http://www.biomedcentral.com/1472-6963/8/35
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remained when adjusting for socioeconomic and insur-
ance status, even when medical conditions were similar.
Other studies report that immigrants with less economic
resources have a decreased probability of emergency, pri-
mary care, and pharmaceutical expenses than the natural-
ized population of the US [17]. Recently arrived
immigrants tend to be poorer, and therefore have more
economic and cultural barriers to accessing health care
due to language and racial or ethnic biases which would
also affect their consumption of medications [18,19]. It is
important to note that the consumption of medications is
related to access to health care services and therefore
results observed in countries without a universal health
system may be not applicable to countries that have one,
such as Spain.
The fourth factor that may affect pharmaceutical con-
sumption is the possibility that immigrants are healthier
than native-born patients. There is some evidence of this
phenomenon in the literature, which has been described
as the "healthy immigrant effect". According to Gushulak,
the healthy immigrant effect is related to three conditions,
a) existing differences in many diseases between wealthy
and less wealthy nations, particularly for lifestyle-associ-
ated diseases (diet, exercise, substance abuse); b) differ-
ences in immigrants' perception of health and disease
(compared to the host population) which causes them to
seek and utilize health services at levels less than the host
population, and c) the process of migration itself which
favors youth and health [20]. Some other factors that can
influence the differential health of immigrants are factors
related to the host country and its immigration policies.
For example, distance to the host country, systematic
health screening of immigrants, etc. At present, Spain does
not require a health certificate for a residence permit or
registration in their municipality of residence, and there
are many immigrants that are not identified by normal
government oversight.
A study that supports the healthy immigrant effect is
Kennedy  et al, which examined the health outcomes,
health behaviors, and socio-economic characteristics of
immigrants from a range of countries to the USA, Canada,
the UK, and Australia. Some of their findings were: a) the
proportion of immigrants with a chronic condition was
less prevalent than in the native-born population, b) the
foreign-born tended to report better health than the
native-born with the exception of Canada, where the
native-born reported 'better' health, and c) positive self-
selection for recent immigrants was present even for
immigrants with relatively low levels of education [21].
Bischoff et al, found evidence that the healthy immigrant
effect was related to the immigrant's country of origin
when studying health disparities between immigrant
groups in Switzerland and the Swiss population [22].
Their results show that the self-reported health of "North-
ern immigrants" (people from Germany and France) did
not differ significantly from that of the majority Swiss
population, whereas "Southern immigrants" (people
from Italy, Former Yugoslavia, Portugal, Spain and Tur-
key) reported lower levels of health in several areas. Simi-
larly, Wiking et al analyzed the association between
ethnicity and poor self-reported health in immigrants to
Sweden from Poland, Turkey and Iran and the Swedish
population [23]. Among men from Iran and Turkey there
was a threefold increased risk of poor self-reported health
than in Swedes, while the risk was five times higher for
women. When socioeconomic status was included in the
logistic model the risk decreased slightly. They concluded
that the strong association between ethnicity and poor
self-reported health seems to be mediated by socioeco-
nomic status, acculturation, and discrimination. In
Amsterdam, Reijneveld et al found that immigrants from
Turkey, Morocco, and former Dutch colonies had
increased risks of poor self-reported health compared
with the majority population [24]. The authors concluded
that the socioeconomic circumstances of ethnic minori-
ties often explain their adverse health status instead of
racial and biological factors.
There is only limited data on the health status of immi-
grants as compared to Spanish-born individuals. Car-
rasco-Garrido  et al in 2003 estimated that 80% of
Spanish-born individuals and 77% of immigrants
assessed their health status as very good or good [25]. In
addition, a higher proportion of immigrants reported
having made at least one emergency visit in the preceding
12 months, and/or having been hospitalized, in the pre-
ceding year. These results would support the hypothesis
that immigrants in Spain do not have a better health sta-
tus than Spanish-born individuals. Consistent with our
results, Carrasco-Garrido et al also found that less immi-
grants consumed medications than the Spanish popula-
tion (42.6% and 49.9%, respectively) [25]. Another study,
published in Barcelona (Spain) in 2005, shows clear dif-
ferences in the use of medications during pregnancy in
women from Spain and other Western countries as com-
pared to a group of women composed of women from
other areas, such as Africa, Eastern Europe, Asia or South
America [26]. Groups formed of Spanish and Western
European women were more similar in their pharmaceu-
tical consumption. These two groups took the most folic
acid and groups from Asian countries took the least.
Immigrant groups in Lleida, when compared to Spanish-
born individuals, have poorer living conditions, lower
socioeconomic status, and are poorly acculturated due to
the recent nature of immigration in Spain. Based on these
studies, and the findings mentioned earlier that low soci-BMC Health Services Research 2008, 8:35 http://www.biomedcentral.com/1472-6963/8/35
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oeconomic level has a strong negative impact on health
status, we think that the differences in pharmaceutical
consumption that we found in our study are not due to a
better health status of the immigrants.
Limitations
The main limitation of our study is the lack of informa-
tion on the health status and socioeconomic level of
patients, which makes it difficult to determine to what
extent observed differences in pharmaceutical consump-
tion are a consequence of existing health differences, soci-
oeconomic disparities or due to compliance or
prescribing differences. There is a need for more informa-
tion on the health status and socioeconomic variables of
immigrant groups in Spain, as well as information on
both native-born and immigrant groups that use health
services.
A second limitation is the insufficient information availa-
ble by origin group. We have observed differences in phar-
maceutical consumption by to zone of origin.
Nevertheless, the age-adjusted relative risks estimates are
not precise enough to consider our results reliable. It
would be interesting to study this issue in future studies.
Among other limitations, we should emphasize the fact
that data were not collected on prescriptions written out-
side the public health care system or for those medica-
tions that do not require a prescription. There is a reliable
registration system for patients assigned to a family physi-
cian and treated in primary care centers [27]. Although
about 25% of the Catalan population has some private
insurance coverage in addition to NHS coverage, estima-
tions place purchases outside the public health system at
2.2% of all prescriptions sold in the Health Region, which
we do not believe is large enough to modify our results
substantially [2]. Nevertheless, prescriptions written by
the physician do not always reach the pharmacy and incur
a pharmaceutical expense. There are some studies that cal-
culate that one in twenty prescriptions are never filled in
a pharmacy, with this number being greater in some envi-
ronments and in patients with specific problems [28]. It
would be interesting to quantify this movement in our
study area and understand the motivations for this type of
behavior.
The findings presented here indicate a need for broader
study of this issue, not only from a quantitative perspec-
tive but also using a qualitative approach, in order to bet-
ter understand differential medication expenses between
immigrants and native-born individuals [28]. There are
some key questions that need to be addressed: Are doctors
prescribing less expensive medications to one group as
compared to another? Are immigrants not complying
with their prescribed treatments? Are immigrants more
healthy than the Spanish-born population? Are there
important differences between immigrant groups by area
of origin?
Conclusion
Pharmaceutical expenses are much lower for immigrants
with respect to Spanish-born patients, when adjusting for
age and sex, both in the percentage of prescriptions filled
at pharmacies, the number of containers of medication
obtained, and the prices of the medications used. Future
studies should explore the causes of these differences and
whether they produce health inequalities [29]. Further-
more, these studies will be more robust if they are sup-
ported by data on the health status and socioeconomic
levels of the immigrant and native populations, in order
to address the "healthy immigrant effect", as well as to
more directly assess factors influencing medication use.
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